Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of, October 2019

Commission File Number 001-37652

 

Midatech Pharma PLC

(Translation of registrant’s name into English)

Oddfellows House,

19 Newport Road,

Cardiff, CF24 0AA, United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F x  Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ 

 

 

 

 

SUBMITTED HEREWITH

 

Attached to the Registrant’s Form 6-K filing for the month of October 2019, and incorporated by reference herein, is:

Exhibit No.		Description
99.1		Press release, dated October 8, 2019 entitled “Commencement of MTD201 Phase 1 Study”

 

 

SIGNATURE 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

						Midatech Pharma PLC
Date: October 9, 2019						By:		/s/ Stephen Stamp
								Stephen Stamp Chief Financial Officer

 

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press release, dated October 8, 2019 entitled “Commencement of MTD201 Phase 1 Study”